Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Hims and Hers Health Inc (HIMS) vs InMode Ltd (INMD) Price & Performance

Hims and Hers Health IncTrade
InMode LtdTrade

Price performance (Past 24H)

Key statistics

Hims and Hers Health Inc vs InMode Ltd — how do they compare? Hims and Hers Health Inc trades at $32.37 (market cap $7.57B), while InMode Ltd trades at $15.36 (market cap $882.90M). The key difference: Hims and Hers Health Inc is far larger — about 8.6× InMode Ltd's market cap, and InMode Ltd is trading nearer its 52-week high, Hims and Hers Health Inc nearer its low. Which is the better fit depends on your goals.

HIMSINMD
Market Cap
$7.57B$882.90M
Sector
HealthTechnology
52-Week High
$66.18$16.62
52-Week Low
$14.52$12.76
Enterprise Value
$7.95B$350.57M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Hims and Hers Health Inc

Hims & Hers Health trades at $32.70, down 0.43% on the day, with a bearish technical signal despite bullish moving averages. The company reported $2.35 billion in 2025 revenue but swung to a projected net loss for 2026, with mixed quarterly earnings results. Recent news highlights executive changes and anticipation for Q2 2026 results on August 10, 2026, with analyst sentiment leaning toward a Buy consensus.

The outlook is cautious due to profitability concerns and high valuation multiples, but growth opportunities in weight-loss and telehealth services offer potential. Key risks include execution challenges and regulatory scrutiny. The stock presents a speculative growth play with a consensus price target of $33.57, slightly above the current price.

InMode Ltd

INMD trades at $15.36, down 0.71% on the day, with a bullish technical signal from moving averages but a neutral reading from oscillators. The company maintains strong profitability with a 77.84% gross margin and 23.27% net margin, though Q1 2026 earnings missed expectations. Recent news includes an unsolicited acquisition offer of $16.75 per share from Steel Partners and upcoming Q2 2026 results on August 5, 2026.

The stock presents a mixed outlook: attractive valuation multiples and a solid balance sheet support upside, but risks include earnings volatility, shareholder activism, and a securities fraud investigation. Analyst consensus is a $16.50 price target with a balanced buy/hold rating split, suggesting cautious optimism near-term.

Returns comparison

Trailing returns across standard periods

About Hims and Hers Health Inc

Hims & Hers is a multi-specialty telehealth platform that provides personalized health and wellness products. It offers access to medical providers and treatments for hair loss, sexual health, and skincare.

Read more on HIMS

About InMode Ltd

InMode provides innovative medical technologies for minimally invasive surgical procedures. Its platforms use radiofrequency (RF) energy for aesthetic treatments like body contouring and skin tightening.

Read more on INMD